文献速递类风湿关节炎

类风湿关节炎中利妥昔单抗剂量依赖性感染风险并非通过循环免疫球蛋白、中性粒细胞或B细胞介导

Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究为REDO试验的事后分析,比较不同利妥昔单抗剂量组及不同时间段的感染发生率,并采用逐步中介分析评估循环B细胞计数、免疫球蛋白水平、中性粒细胞计数及糖皮质激素/改善病情抗风湿药使用是否介导剂量依赖性感染风险。结果显示上述因素均未解释REDO试验中观察到的剂量依赖性感染风险,且发现输注后短期内感染率较高的时间依赖趋势。

要点

  • REDO试验事后分析证实利妥昔单抗存在剂量依赖性感染风险。
  • 循环B细胞、免疫球蛋白、中性粒细胞及药物使用未介导该剂量依赖性风险。
  • 观察到输注后短期内感染率较高的时间依赖趋势。

核心结论

  • REDO试验的二次分析证实了观察到的剂量依赖性感染风险,且未发现中介通路。
  • 感染风险在利妥昔单抗输注后短期内较高。

研究设计与样本

  • REDO试验的事后分析,采用泊松回归比较利妥昔单抗不同剂量组间及不同时间段间的感染发生率,并采用逐步中介分析评估潜在中介因素。

主要发现

  • 所研究的潜在中介因素(循环B细胞计数、免疫球蛋白水平、中性粒细胞计数及药物使用)均未解释REDO试验中观察到的剂量依赖性感染风险。
  • 发现感染风险存在时间依赖趋势,利妥昔单抗输注后短期内感染率较高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rituximab (RTX) is a safe and effective treatment for RA. A dose-dependent infection risk was found in the REDO trial. Some studies associate RTX use with higher infection risks, possibly explained by low immunoglobulin levels and/or neutropenia. Additionally, a higher infection risk shortly after RTX infusion is reported. The objectives of this study were (i) to compare incidence rates of infections between doses and over time, and (ii) to assess B-cell counts, immunoglobulin levels, neutrophil counts and corticosteroid/disease modifying rheumatic drug use as mediating factors between RTX study dose and infection risk. METHODS: Post hoc analyses of the REDO trial were performed. Infection incidence rates between RTX dosing groups and between time periods were compared using Poisson regression. A step-wise mediation analysis was performed to investigate if any of the factors mentioned above act as a mediator in the observed dose-dependent difference in infection risk. RESULTS: The potential mediators that were investigated (circulating B-cell counts, immunoglobulin levels, neutrophil counts and drug use) did not explain the dose-dependent infection risk observed in the REDO trial. Additionally, a trend towards a time-dependent infection risk was found, with higher infection rates shortly after RTX infusion. CONCLUSIONS: These secondary analyses of the REDO trial confirmed the observed dose-dependent infection risk. Additionally, we found that infection risks were higher shortly after RTX infusion. However, a mediating pathway was not found.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Opdam MAA, de Leijer JH, den Broeder N, et al. Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. Rheumatology (Oxford). 2022. PMID: 35686851. doi:10.1093/rheumatology/keac318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。